Misyo (Methadone Hydrochloride)

• Methadone Hydrochloride is used in opioid‑related pathways to control dependence and provide analgesia.
• Opioid dependence treatment: helps stabilize patients during withdrawal and supports long‑term abstinence.
• Chronic pain management: offers long‑acting analgesic effect for severe, persistent pain that is not adequately controlled by non‑opioid agents.

• Methadone Hydrochloride acts primarily as a full agonist at the mu‑opioid receptor, producing analgesia and reducing withdrawal symptoms. It also antagonizes NMDA receptors, which may lessen opioid tolerance, and inhibits the reuptake of serotonin and norepinephrine, contributing to its analgesic profile and mood‑modulating effects.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Constipation: reduced gastrointestinal motility.
• Nausea or vomiting: gastrointestinal upset.
• Drowsiness or sedation: central nervous system depression.
• Sweating: autonomic activation.
• Dry mouth: decreased salivary flow.
• Mood changes: irritability or anxiety.

Serious or Rare Side Effects

• Respiratory depression: risk of life‑threatening hypoventilation.
• Cardiac arrhythmias: QT‑interval prolongation may lead to torsades de pointes.
• Severe hypotension: sudden drop in blood pressure.
• Seizures: rare but reported in high‑dose exposure.

• Before prescribing Misyo, clinicians should evaluate patient history and monitor for specific risks.
• Assess cardiac risk: obtain baseline ECG to evaluate QT interval.
• Screen for respiratory disorders: monitor patients with COPD or sleep apnea closely.
• Avoid abrupt discontinuation: taper dose to prevent withdrawal.
• Pregnancy and lactation: weigh benefits against potential fetal or neonatal effects.
• Drug‑specific counseling: advise patients not to operate machinery while sedated.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Methadone Hydrochloride can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase methadone plasma levels.
• QT‑prolonging agents (e.g., haloperidol, quinidine): heighten risk of cardiac arrhythmias.
• CNS depressants (e.g., benzodiazepines, barbiturates): potentiate respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP2B6 inducers (e.g., rifampin, carbamazepine): may reduce methadone efficacy.
• Antidepressants affecting serotonin (e.g., SSRIs): increase risk of serotonin syndrome.
• Alcohol: additive sedative effects requiring dose adjustment.